NCT05188989

Efficacy and Safety Study of TPN171H Tablets in Erectile Dysfunction.

A Multi-Center ,Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of TPN171H in Patients With Erectile Dysfunction

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 765 (actual)
• Sponsor: Vigonvita Life Sciences · Industry
• Sex: Male
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, randomized, double blind, placebo-controlled, parallel design study to evaluate the efficacy and safety of TPN171H in men with erectile dysfunction.

Conditions

• Erectile Dysfunction

Interventions

Type	Name	Description
DRUG	TPN171H 2.5mg group	TPN171H 2.5mg taken orally on demand 0.5-4 hour prior to sexual intercourse
DRUG	TPN171H 5mg group	TPN171H 5mg taken orally on demand 0.5-4 hour prior to sexual intercourse
DRUG	TPN171H 10mg group	TPN171H 10mg taken orally on demand 0.5-4 hour prior to sexual intercourse
DRUG	Placebo group	Placebo taken orally on demand 0.5-4 hour prior to sexual intercourse

Timeline

• Start date: 2021-12-31
• Primary completion: 2023-02-14
• Completion: 2023-02-14
• First posted: 2022-01-12
• Last updated: 2023-03-07

Locations

49 sites across 1 country: China